论文部分内容阅读
目的探讨Mirk/Dyrk1B在人配对宫颈癌组织中表达的临床意义及其与其他耐药基因之间的相关性。方法实时荧光定量PCR检测Mirk/Dyrk1B在正常宫颈组织、癌旁组织和宫颈癌组织的表达,免疫组织化学(IHC)检测Mirk/Dyrk1B和3个耐药基因(Pg P、TopoⅡ和GST-π)蛋白在70例宫颈癌组织、40例癌旁宫颈组织和正常宫颈组织的表达水平,分析Dyrkl B和3个编码耐药基因蛋白在配对宫颈癌组织中的表达情况以及临床意义。结果 Mirk/Dyrk1B在宫颈癌组织的表达显著高于癌旁组织和正常宫颈组织。Dyrkl B与组织学分化程度有显著相关性(P<0.05),Dyrk1B与宫颈癌的临床分期和淋巴结转移无显著相关性(P>0.05)。Mirk/Dyrk1B和GST-π存在相关性(P<0.01)。结论Mirk/Dyrk1B在宫颈癌组织中高度表达,并与耐药基因GST-π蛋白表达相关,参与宫颈癌的发生和多药耐药性,可能成为临床早期诊断的肿瘤标记和一个新的目标基因,用于治疗宫颈癌。
Objective To investigate the clinical significance of Mirk / Dyrk1B expression in human paired cervical cancer and its relationship with other drug resistance genes. Methods The expression of Mirk / Dyrk1B in normal cervical tissue, paracancerous tissues and cervical cancer tissues was detected by real-time fluorescence quantitative PCR. Mirk / Dyrk1B and three drug resistance genes (Pg P, TopoⅡ and GST-π) were detected by immunohistochemical staining Protein expression in 70 cases of cervical cancer tissue, 40 cases of paracancer cervical tissue and normal cervical tissue, analysis of the expression of Dyrkl B and 3 genes encoding resistance in paired cervical cancer and its clinical significance. Results The expression of Mirk / Dyrk1B in cervical cancer tissues was significantly higher than that in paracancerous tissues and normal cervical tissues. There was a significant correlation between Dyrkl B and histological differentiation (P <0.05). There was no significant correlation between Dyrkl B and clinical stage and lymph node metastasis (P> 0.05). There was a correlation between Mirk / Dyrk1B and GST-π (P <0.01). Conclusions Mirk / Dyrk1B is highly expressed in cervical cancer tissues and is associated with the expression of GST-π protein, which is involved in the occurrence of cervical cancer and multidrug resistance. It may be a tumor marker and a new target gene for early clinical diagnosis , For the treatment of cervical cancer.